Accelrys To Provide Technology For Functional Annotation Of Confirmant’s Protein Atlas Of The Human Genome(Tm)

SAN DIEGO and ABINGDON, England, February 11 2003

Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (NASDAQ: PCOP), and Confirmant Ltd., a provider of innovative bio-information, today announced a technology software alliance that will result in a novel database consisting of highly annotated proteins which could provide the pharmaceutical industry with crucial data for prioritizing the selection of drug targets and accelerating drug discovery.

Under the terms of the agreement, Confirmant will license Accelrys’ GeneAtlas(TM) software product, an application for high throughput sequence and structure-based functional annotation. Confirmant will use GeneAtlas(TM) to annotate the function of protein sequences contained within The Protein Atlas of the Human Genome(TM), Confirmant’s comprehensive database of proteins that can be directly mapped back to the human genome.

These annotations will be commercially available from Confirmant within Accelrys’ Discovery Studio AtlasStore(TM) database (DS AtlasStore) an Oracle-based enterprise-wide database that integrates protein sequence, structure and annotation data. This new database will be marketed by both parties as a complementary and valuable addition to the Protein Atlas.

“Through their unique approach, Confirmant has made significant progress in uncovering the potential of genomics and genetics for drug discovery,” said Dr. Scott Kahn, chief science officer, Accelrys. “By linking the experimental proteomic data in Confirmant’s Protein Atlas with the annotations in DS AtlasStore, Accelrys and Confirmant will be able to provide the drug discovery industry with a new level of information for disease-related-proteins.”

“We are pleased to be working with Accelrys to supply scientists with an unambiguous protein-centric view of the human genome,” said David Palmer, CEO of Confirmant. “We believe the combination of our extensive proteomic data with Accelrys’ annotation tools will be extremely powerful in helping scientists develop new therapeutic and diagnostic products.”

About Confirmant

Confirmant Ltd. provides novel and unique post-genomic bio-information to the pharmaceutical, biotechnology and medical research communities. Based on experimentally derived human protein sequence determination, Confirmant’s first database product, The Protein Atlas of the Human Genome (TM), is the first definitive database of human proteins and already includes some 11,000 protein-coding genes and their fine structure as well as the protein variants they encode. This information will more reliably aid in the identification and validation of drug targets and disease biomarkers, resulting in faster and more effective development of new treatments and diagnostics. Confirmant is a joint venture between Oxford GlycoSciences (LSE: OGS; NASDAQ: OGSI) and Marconi (MONI) and is based in Abingdon in the United Kingdom. For more information, go to http://www.confirmant.com